Antimicrobial
Stewardship,
Reimagined.
AntiBiom delivers AI-powered clinical decision support for antimicrobial prescribing — integrating real-time lab data, resistance analytics, and evidence-based guidance at the point of care.
Trusted by early access clinicians across 12 hospitals
700,000 deaths annually
from antimicrobial resistance — projected to reach 10 million by 2050.
Antimicrobial resistance (AMR) is one of the most urgent threats in modern medicine. Inappropriate antibiotic prescribing accelerates resistance, increases patient mortality, and drives up healthcare costs.
Structured stewardship programs have been shown to reduce inappropriate antibiotic use by up to 30% — yet most institutions lack the clinical decision support infrastructure to implement them effectively at scale.
AntiBiom closes that gap.
Clinical intelligence,
built for stewardship teams.
Real-Time Lab Integration
Bidirectional LIS connectivity surfaces culture sensitivities and susceptibility data directly within clinical workflows.
Resistance Pattern Analytics
Institutional antibiograms and trend analysis to track resistance emergence and benchmark against regional and national data.
Clinical Pharmacist Workflows
Structured review queues, IV-to-oral conversion prompts, and de-escalation alerts designed for pharmacist-led stewardship rounds.
Regulatory Compliance Reporting
Automated reporting for NHSN, CMS, and Joint Commission stewardship requirements — reducing administrative burden on clinical teams.
Built for every member
of the stewardship team.
Physicians
Receive context-aware prescribing guidance integrated into your existing clinical workflow — without disrupting the patient encounter.
Clinical Pharmacists
Lead stewardship rounds with structured review tools, de-escalation prompts, and real-time culture data at your fingertips.
Microbiologists
Contribute institutional resistance data and receive automated alerts when emerging resistance patterns require clinical escalation.
Hospital Administrators
Track stewardship program performance, meet regulatory reporting requirements, and demonstrate measurable outcomes to accreditation bodies.
Be among the first clinicians
to access AntiBiom.
We're onboarding a limited cohort of early access institutions. Join the waitlist to secure your place and shape the platform's development.